These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15466177)

  • 1. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma.
    Wei JS; Greer BT; Westermann F; Steinberg SM; Son CG; Chen QR; Whiteford CC; Bilke S; Krasnoselsky AL; Cenacchi N; Catchpoole D; Berthold F; Schwab M; Khan J
    Cancer Res; 2004 Oct; 64(19):6883-91. PubMed ID: 15466177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated cross-platform prognosis study on neuroblastoma patients.
    Chen QR; Song YK; Wei JS; Bilke S; Asgharzadeh S; Seeger RC; Khan J
    Genomics; 2008 Oct; 92(4):195-203. PubMed ID: 18598751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-gene expression signature model for risk stratification of patients with neuroblastoma.
    Garcia I; Mayol G; Ríos J; Domenech G; Cheung NK; Oberthuer A; Fischer M; Maris JM; Brodeur GM; Hero B; Rodríguez E; Suñol M; Galvan P; de Torres C; Mora J; Lavarino C
    Clin Cancer Res; 2012 Apr; 18(7):2012-23. PubMed ID: 22328561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
    Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.
    Harttrampf AC; Chen Q; Jüttner E; Geiger J; Vansant G; Khan J; Kontny U
    BMC Res Notes; 2017 Aug; 10(1):413. PubMed ID: 28818093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial neural network classifier predicts neuroblastoma patients' outcome.
    Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
    BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
    London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
    J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
    Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J
    Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
    Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
    J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
    Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
    J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management strategy in neuroblastoma].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
    De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
    Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L
    Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.